• Davi Santana Sousa Universidade Federal dos Vales do Jequitinhonha e Mucuri
  • Jessica Santa Brígida da Silva Universidade Tiradentes
  • Laís Bispo Silva Instituto de Estudos da Saúde & Gestão Sérgio Feitosa
  • Yasmin dos Santos Interfisio Cursos & Treinamentos Profissionais
  • Marcos Gabriel do Nascimento Junior Universidade Federal de Sergipe
  • Diego Mendes Xavier Universidade Federal dos Vales do Jequitinhonha e Mucuri
  • Maria Jane das Virgens Aquino Universidade Federal de Sergipe




Cannabis, Quality of life, Naturals Extracts, Lennox-Gastaut


Lennox-Gastaut Syndrome is a common and intractable epileptic encephalopathy. It accounts for about 5% of all childhood epilepsies, causing symptoms such as seizures, behavioral changes and delay in child development. The treatment for this syndrome occurs in a combined way between the physical therapy approach and drug intervention. However, because anticonvulsants have high levels of toxicity and effective incapacity for treatment, new approaches have been analyzed as a proposal for therapeutic intervention, one of them being the use of medicinal plants such as Cannabis sativa. Based on this, this study aims to analyze the effectiveness of cannabidiol in clinical application for patients with Lennox-Gastaut Syndrome, through a systematic literature review. To carry out this study, articles in English, published in the last five years, in the MEDLINE/PubMed, Science Direct, Web of Science, Scopus, BVS/LILACS, SciELO, CAPES Periodicals, CENTRAL and CINAHL Complete databases were recruited from of the descriptors Cannabidiol and Lennox-Gastaut Syndrome, combined by the Boolean AND operator. The review research was registered in PROSPERO with the code CRD42021229584 and followed the criteria of the PICO strategy. From the analysis and careful investigation of the results of the databases, two articles were included in the study, selected from the screening of 503 studies. The discussion of the articles was carried out using criteria that define the pharmacological parameters, the side effects of cannabidiol and the effects on the individuals' quality of life. Therefore, the study demonstrated that cannabidiol is effective in the clinical condition of patients with Lennox-Gastaut Syndrome, but further studies are needed to more selectively investigate toxicity, ideal dosage, product validity, as well as possible drug interactions and side effects.


Não há dados estatísticos.

Biografia do Autor

Davi Santana Sousa, Universidade Federal dos Vales do Jequitinhonha e Mucuri

Graduando em Fisioterapia pela Universidade Federal dos Vales do Jequitinhonha e Mucuri


Camfield PR. Definition and natural history of Lennox-Gastaut syndrome. Epilepsia. 2011 Aug;52 Suppl 5:3-9. doi: 10.1111/j.1528-1167.2011.03177.x.

Asadi-Pooya AA. Lennox-Gastaut syndrome: a comprehensive review. Neurol Sci. 2018 Mar;39(3):403-414. doi: 10.1007/s10072-017-3188-y.

Trevathan E, Murphy CC, Yeargin-Allsopp M. Prevalence and descriptive epidemiology of Lennox-Gastaut syndrome among Atlanta children. Epilepsia. 1997 Dec;38(12):1283-8. doi: 10.1111/j.1528-1157.1997.tb00065.x.

Goldsmith IL, Zupanc ML, Buchhalter JR. Long-term seizure outcome in 74 patients with Lennox-Gastaut syndrome: effects of incorporating MRI head imaging in defining the cryptogenic subgroup. Epilepsia. 2000 Apr;41(4):395-9. doi: 10.1111/j.1528-1157.2000.tb00179.x.

Verrotti A, Striano P, Iapadre G, Zagaroli L, Bonanni P, Coppola G, Elia M, Mecarelli O, Franzoni E, Liso P, Vigevano F, Curatolo P. The pharmacological management of Lennox-Gastaut syndrome and critical literature review. Seizure. 2018 Dec;63:17-25. doi: 10.1016/j.seizure.2018.10.016.

Ferlazzo E, Adjien CK, Guerrini R, Calarese T, Crespel A, Elia M, Striano P, Gelisse P, Bramanti P, di Bella P, Genton P. Lennox-Gastaut syndrome with late-onset and prominent reflex seizures in trisomy 21 patients. Epilepsia. 2009 Jun;50(6):1587-95. doi: 10.1111/j.1528-1167.2008.01944.x.

Michoulas A, Farrell K. Medical management of Lennox-Gastaut syndrome. CNS Drugs. 2010 May;24(5):363-74. doi: 10.2165/11530220-000000000-00000.

Amrutkar C, Riel-Romero RM. Lennox Gastaut Syndrome. 2021 Aug 9. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–.

Billakota S, Devinsky O, Marsh E. Cannabinoid therapy in epilepsy. Curr Opin Neurol. 2019 Apr;32(2):220-226. doi: 10.1097/WCO.0000000000000660.

Brodie MJ, Ben-Menachem E. Cannabinoids for epilepsy: What do we know and where do we go? Epilepsia. 2018 Feb;59(2):291-296. doi: 10.1111/epi.13973.

Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. BMJ. 2009;339(7716):332-336. doi:10.1136/bmj.b2535

McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement. J Clin Epidemiol. 2016 Jul;75:40-6. doi: 10.1016/j.jclinepi.2016.01.021

Andre CM, Hausman JF, Guerriero G. Cannabis sativa: The Plant of the Thousand and One Molecules. Front Plant Sci. 2016;7:19. Published 2016 Feb 4. doi:10.3389/fpls.2016.00019

Atakan Z. Cannabis, a complex plant: different compounds and different effects on individuals. Ther Adv Psychopharmacol. 2012;2(6):241-254. doi:10.1177/2045125312457586

Rosenberg EC, Patra PH, Whalley BJ. Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection. Epilepsy Behav. 2017 May;70(Pt B):319-327. doi: 10.1016/j.yebeh.2016.11.006

Katona I. Cannabis and Endocannabinoid Signaling in Epilepsy. Handb Exp Pharmacol. 2015;231:285-316. doi: 10.1007/978-3-319-20825-1_10.

Silvestro S, Mammana S, Cavalli E, Bramanti P, Mazzon E. Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials. Molecules. 2019 Apr 12;24(8):1459. doi: 10.3390/molecules24081459.

Franco V, Perucca E. Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy. Drugs. 2019 Sep;79(13):1435-1454. doi: 10.1007/s40265-019-01171-4.

Muller C, Morales P, Reggio PH. Cannabinoid Ligands Targeting TRP Channels. Front Mol Neurosci. 2019 Jan 15;11:487. doi: 10.3389/fnmol.2018.00487.

Vilela LR, Lima IV, Kunsch ÉB, Pinto HPP, de Miranda AS, Vieira ÉLM, de Oliveira ACP, Moraes MFD, Teixeira AL, Moreira FA. Anticonvulsant effect of cannabidiol in the pentylenetetrazole model: Pharmacological mechanisms, electroencephalographic profile, and brain cytokine levels. Epilepsy Behav. 2017 Oct;75:29-35. doi: 10.1016/j.yebeh.2017.07.014.

Laprairie RB, Bagher AM, Kelly ME, Denovan-Wright EM. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol. 2015 Oct;172(20):4790-805. doi: 10.1111/bph.13250.

Tham M, Yilmaz O, Alaverdashvili M, Kelly MEM, Denovan-Wright EM, Laprairie RB. Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors. Br J Pharmacol. 2019 May;176(10):1455-1469. doi: 10.1111/bph.14440.

Thomas A, Baillie GL, Phillips AM, Razdan RK, Ross RA, Pertwee RG. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol. 2007 Mar;150(5):613-23. doi: 10.1038/sj.bjp.0707133.

Chen KA, Farrar MA, Cardamone M, Lawson JA. Cannabis for paediatric epilepsy: challenges and conundrums. Med J Aust. 2018 Feb 19;208(3):132-136. doi: 10.5694/mja17.00699.

Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, Greenwood SM, Roberts C, Checketts D, VanLandingham KE, Zuberi SM; GWPCARE3 Study Group. Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. N Engl J Med. 2018 May 17;378(20):1888-1897. doi: 10.1056/NEJMoa1714631.

Koo CM, Kim SH, Lee JS, Park BJ, Lee HK, Kim HD, Kang HC. Cannabidiol for Treating Lennox-Gastaut Syndrome and Dravet Syndrome in Korea. J Korean Med Sci. 2020 Dec 28;35(50):e427. doi: 10.3346/jkms.2020.35.e427.

Thiele EA, Marsh ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C, Lyons PD, Taylor A, Roberts C, Sommerville K; GWPCARE4 Study Group. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018 Mar 17;391(10125):1085-1096. doi: 10.1016/S0140-6736(18)30136-3.

Gonçalves J, Rosado T, Soares S, et al. Cannabis and Its Secondary Metabolites: Their Use as Therapeutic Drugs, Toxicological Aspects, and Analytical Determination. Medicines (Basel). 2019;6(1):31. Published 2019 Feb 23. doi:10.3390/medicines6010031

Rosenberg EC, Louik J, Conway E, Devinsky O, Friedman D. Quality of Life in Childhood Epilepsy in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol. Epilepsia. 2017 Aug;58(8):e96-e100. doi: 10.1111/epi.13815.

Strzelczyk A, Schubert-Bast S. Expanding the Treatment Landscape for Lennox-Gastaut Syndrome: Current and Future Strategies. CNS Drugs. 2021 Jan;35(1):61-83. doi: 10.1007/s40263-020-00784-8.

Raucci U, Pietrafusa N, Paolino MC, Di Nardo G, Villa MP, Pavone P, Terrin G, Specchio N, Striano P, Parisi P. Cannabidiol Treatment for Refractory Epilepsies in Pediatrics. Front Pharmacol. 2020 Sep 29;11:586110. doi: 10.3389/fphar.2020.586110.

Stockings E, Zagic D, Campbell G, Weier M, Hall WD, Nielsen S, Herkes GK, Farrell M, Degenhardt L. Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence. J Neurol Neurosurg Psychiatry. 2018 Jul;89(7):741-753. doi: 10.1136/jnnp-2017-317168.

Gaston TE, Szaflarski M, Hansen B, Bebin EM, Szaflarski JP; UAB CBD Program. Quality of life in adults enrolled in an open-label study of cannabidiol (CBD) for treatment-resistant epilepsy. Epilepsy Behav. 2019 Jun;95:10-17. doi: 10.1016/j.yebeh.2019.03.035.




Como Citar

Sousa, D. S., da Silva, J. S. B., Silva, L. B., dos Santos, Y., Junior, M. G. do N., Xavier, D. M., & Aquino, M. J. das V. (2023). EFFECT OF THE USE OF CANNABIDIOL ON THE TREATMENT OF LENNOX-GASTAUT SYNDROME: A SYSTEMATIC REVIEW. Saúde (Santa Maria), 48(1). https://doi.org/10.5902/2236583468765



Artigos de Revisão

Artigos mais lidos pelo mesmo(s) autor(es)